You are now leaving XTANDI.com
The website you are about to visit is not owned or controlled by Astellas. Astellas are not responsible for the information or services on this site.
The U.S. Food and Drug Administration’s approval of XOSPATA® (gilteritinib) is a proud moment for Astellas. This approval is about more than pride, though — it’s about gratitude. When products that stand to make a difference in patients’ lives come to the market, it’s important to remember the faces behind the achievement. And so, today, I want to say thank you.
When I think about gratitude, I think about patients who chose to be part of our clinical trials in the face of a devastating diagnosis. Facing their own mortality, they chose to help others, which takes an enormous amount of courage and selflessness. I am grateful for the choice that every patient made to participate in the XOSPATA clinical trials that brought us here today. I am also thankful for the caregivers who supported their loved ones’ participation in our trials.
In addition to patients and to caregivers, I’m grateful to the regulators who understood the desperate need of those suffering. I’m also thankful for the physicians who guided XOSPATA’s clinical development, the medical community advocates who recognized the unmet medical need, and finally, the researchers who strove tirelessly in the lab to advance science.
To all of those who participated in XOSPATA’s clinical trials and approval, thank you.
At Astellas, we are focused on “changing tomorrow” for patients suffering from diseases. And today, together, we have given new hope to patients and taken an important step towards accomplishing our goal.
Get only the email alerts you want.
For media inquiries and reporter requests, please email us at corporate.communications@us.astellas.com.
Our communications team will respond to verified media requests within 24-48 hours as appropriate.
If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
The site uses cookies to provide you with a more responsive and personalized service and to analyze site traffic. By using this site, you accept our use of cookies as described in our privacy policy. Please read our privacy policy for more information on the cookies we use, the processing of your personal data and how to delete or block the use of cookies.